Taiwan Bio

Taiwan Bio focuses on the innovation and popularization of cell therapy. Through the FAST CGT platform, it effectively reduces costs, enhances treatment efficacy, accelerates development processes, and shortens production cycles, establishing a new milestone in the treatment of chronic and immune-related diseases. Starting from Taiwan, its technologies are gradually expanding globally, collaborating with several renowned American universities and research institutions to build a complete industry ecosystem. With the unique TDM business model, Taiwan Bio provides comprehensive support for cell therapy products in pre-clinical or early clinical stages, from R&D to production, enabling more patients to benefit from cutting-edge cell therapies and move towards a healthier era free of chronic diseases.